Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CREBBP | Q92793 | 1/20 | 0.57 |
| ▸ | TRPM5 | Q9NZQ8 | 12/20 | 0.51 |
| ▸ | CNR1 | P21554 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13064359 | 0.79 | TRPM5 (0.47) | CREBBPTRPM5MEN1KMT2A | |
| SCHEMBL1223744 | 0.78 | TRPM5 (0.53) | TRPM5MEN1KMT2AKDM4E | |
| SCHEMBL1224036 | 0.76 | TRPM5 (0.53) | CREBBPTRPM5CNR1LMNAMEN1 | |
| SCHEMBL28616563 | 0.73 | CREBBP (1.00) | CREBBPCNR1LMNAKMT2AALDH1A1 | |
| SCHEMBL1250185 | 0.72 | ALDH1A1 (0.77) | CREBBPCNR1LMNAMEN1KMT2A | |
| SCHEMBL1223624 | 0.71 | CNR1 (0.64) | CREBBPTRPM5CNR1LMNAMEN1 | |
| SCHEMBL9324289 | 0.71 | LMNA (0.61) | CREBBPTRPM5CNR1LMNAMEN1 | |
| SCHEMBL8528645 | 0.70 | ALDH1A1 (0.71) | CREBBPLMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL21695505 | 0.70 | LMNA (0.74) | CREBBPLMNAKMT2A | |
| SCHEMBL4064250 | 0.69 | EGLN3 (0.65) | CREBBPLMNAMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110033393-A1 | Hydrazone Compounds and Their Use | REDPOINT BIO CORPORATION | 2011-02-10 | — | — | US | disclosed |
| WO-2010132615-A1 | HYDRAZONE COMPOUNDS AND THEIR USE | STEIN PHILIP (US) | 2010-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110033393-A1 | Hydrazone Compounds and Their Use | TRPM5, TRPV5, TRPM8 | CREBBP 2724/4885TRPM5 1/4885CNR1 235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.